2024 ASCO-GU尿路上皮癌热点精读  

Focused review of urothelial carcinoma highlights from the 2024 ASCO-GU symposium

作　　者：鲍一歌 虞巍[2] 何志嵩[2] 魏强[1] Bao Yige;Yu Wei;He Zhisong;Wei Qiang(Department of Urology and Institute of Urology,West China Hospital,Sichuan University,Chengdu 610041 China;Department of Urology,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]四川大学华西医院泌尿外科四川大学华西医院泌尿外科研究所,成都610041 [2]北京大学第一医院泌尿外科,北京100034

出　　处：《中华泌尿外科杂志》2024年第4期254-257,共4页Chinese Journal of Urology

摘　　要：回顾了2024年ASCO-GU会议上关于尿路上皮癌的最新研究,主要讨论了淋巴结阳性肌层浸润性膀胱癌(N_(+)MIBC)的治疗策略和MIBC术后的辅助治疗。N_(+)MIBC患者面临较高的复发风险,需要综合治疗策略。新辅助化疗和免疫治疗的联合方案显示出显著的疗效,此外,保留膀胱治疗和免疫维持治疗在延长无病生存期方面展现出潜力。AMBASSADOR和CheckMate-274研究的结果显示,高危MIBC术后免疫辅助治疗有利于延缓疾病复发。这些进展为高危MIBC患者的治疗提供了新的希望,并可能改善患者的预后。This article reviews the latest research on urothelial carcinoma presented at the 2024 ASCO-CU conference,focusing primarily on the treatment strategies for node-positive muscle-invasive bladder cancer(N_(+)MIBC)and adjuvant therapy post-surgery for muscle-invasive bladder cancer.Patients with N_(+)MIBC are at a higher risk of recurrence and require a comprehensive treatment approach.The combination of neoadjuvant chemotherapy and immunotherapy has demonstrated significant efficacy.Additionally,bladdersparing treatment and immuno-maintenance therapy show promise in improving disease-free survival.The results from the AMBASSADOR and CheckMate-274 studies indicate that postoperative immuno-adjuvant therapy for high-risk MIBC is beneficial in delaying disease recurrence.These advancements offer new hope for the treatment of patients with high-risk MIBC and may potentially improve patient outcomes.

关 键 词：尿路上皮癌 肌层浸润性膀胱癌 肿瘤免疫治疗 ASCO-GU会议 

分 类 号：R737.1[医药卫生—肿瘤]